Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by FDx Advisors Inc.

FDx Advisors Inc. lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 17.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,426 shares of the biopharmaceutical company’s stock after selling 939 shares during the quarter. FDx Advisors Inc.’s holdings in Gilead Sciences were worth $409,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. First Bank & Trust raised its holdings in Gilead Sciences by 0.7% in the fourth quarter. First Bank & Trust now owns 51,929 shares of the biopharmaceutical company’s stock valued at $4,797,000 after acquiring an additional 354 shares in the last quarter. Advyzon Investment Management LLC acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $418,000. Handelsbanken Fonder AB raised its holdings in Gilead Sciences by 9.6% in the fourth quarter. Handelsbanken Fonder AB now owns 590,156 shares of the biopharmaceutical company’s stock valued at $54,513,000 after acquiring an additional 51,453 shares in the last quarter. Sunpointe LLC raised its holdings in Gilead Sciences by 12.0% in the fourth quarter. Sunpointe LLC now owns 4,654 shares of the biopharmaceutical company’s stock valued at $430,000 after acquiring an additional 500 shares in the last quarter. Finally, Global Retirement Partners LLC raised its holdings in Gilead Sciences by 2.2% in the fourth quarter. Global Retirement Partners LLC now owns 8,982 shares of the biopharmaceutical company’s stock valued at $830,000 after acquiring an additional 194 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 713,000 shares of company stock worth $67,945,181 in the last three months. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $110.03 on Friday. The firm’s fifty day moving average price is $95.05 and its 200 day moving average price is $88.38. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $110.11. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The firm has a market cap of $137.13 billion, a price-to-earnings ratio of 297.38, a price-to-earnings-growth ratio of 0.88 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.94 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.87%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is 832.43%.

Analyst Ratings Changes

Several brokerages recently weighed in on GILD. Piper Sandler raised their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Wells Fargo & Company raised their target price on shares of Gilead Sciences from $105.00 to $120.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their price target for the company from $80.00 to $120.00 in a research note on Tuesday. Finally, Wolfe Research assumed coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target on the stock. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $102.08.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.